What are the precautions for Tebentafusp-tebn?

In clinical studies of Tebentafusp-tebn, adverse events such as cytokine release syndrome, skin reactions, and elevated liver enzymes occurred.

1. Cytokine release syndrome (CRS): The symptoms of CRS may include fever, hypotension, hypoxia, chills, nausea, vomiting, rash, elevated transaminases, fatigue and headache, and may be life-threatening. Ensure that health care providers administering tebenforxhave immediate access to medications and resuscitation equipment to manageCRS. Before starting the infusion, make sure the patient's blood is normal. After infusion of tebenforxide, monitor patients closely for signs or symptoms of CRS and provide appropriate treatment. Depending on the persistence and severity of CRS, stop or discontinue tebenforx.

2. Skin reactions: including rash, itching and skin edema. In studies, the median time to onset of skin reactions was 1 day (range: 1-55 days). The median time to improvement to grade ≤1 was approximately 6 days. Monitor patient for skin reactions. If a skin reaction occurs, treat with antihistamines and topical or systemic steroids, depending on the duration and severity of symptoms. Depending on the severity of the skin reaction, discontinue or permanently discontinue tebenforx.

3. Elevated liver enzymes: Patients who experienced elevated ALT/AST in the study initially occurred during the first 3 infusions of tebenforx. Monitor alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total blood bilirubin before initiating and during treatment with tebenforx. Discontinue tebenforx based on severity.

The original drug of Tibenforsi is not currently on the market in China, nor has it been included in medical insurance. After Tebenforx is approved for marketing, there may be less price and other related information. For more drug information and specific prices, please consult a medical consultant.